OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO’s common stock has been repurchased under the existing program since its authorization in July 2024. “We believe OPKO’s shares continue to be significantly undervalued and offer an attractive...
Northern Technologies International Corporation to Announce Fiscal 2025 Second-Quarter Financial Results and Host Conference Call MINNEAPOLIS, April 03, 2025 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC) today announced that it expects to release its fiscal 2025 second-quarter financial results on Thursday, April 10, 2025, before the market opens. A copy of the news release will be available on the Investor Relations section of NTIC’s webpage (). In conjunction with NTIC’s release of its financial and operating results, investors, analysts, and other ...
A director at Opko Health Inc bought 200,000 shares at 1.739USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. ...
Three Directors at Veracyte Inc sold after exercising options/sold 61,876 shares at between 33.339USD and 33.692USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the ...
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth quarter of 2024 and recent weeks include the following: Enrollment and dosing underway by Merck in the Phase 1 Epstein-Barr virus (EBV) vaccine trial. Dosing of patients has commenced for the Phase I study () of an EBV vaccine candidate being deve...
OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Thursday, February 27, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of AZZ Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 3 February 2025 in which we reassessed the appropriateness of the ratings in the context of the re...
Northern Technologies International Corporation Announces Quarterly Cash Dividend MINNEAPOLIS, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Northern Technologies International Corporation (NASDAQ: NTIC), a leading developer of corrosion inhibiting products and services, as well as bio-based and biodegradable polymer resin compounds, today announced that the Board of Directors declared a quarterly cash dividend of $0.07 per share payable on February 12, 2025, to shareholders of record at the close of business on January 29, 2025. About Northern Technologies International Corporation Northern Tec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.